Empowered
by Movement
Our Vision
People with spinal cord injury will enjoy life in the ways that matter to them
Meet Our Team
We are a team of scientists, engineers, and physicians, collectively driven to create therapies that change lives.
We are driven to innovate, with 10 FDA Breakthrough Device Designation awards and nearly 400 issued or pending patents.
Discover Our Therapy
Investigational ARC Therapy™ is targeted stimulation of the spinal cord designed to restore movement, function, and independence in people living with spinal cord injury.
Up-LIFT pivotal trial results published in Nature Medicine
The Up-LIFT study was designed to evaluate the safety and effectiveness of our investigational ARCEX® Therapy to improve upper limb mobility in people with chronic incomplete tetraplegia. The global study was conducted with 65 participants at 14 leading SCI centers in the US, Europe, and Canada.
Highlights* include:
Primary safety and effectiveness endpoints met.
90% of participants improved strength or function of their upper limbs.
87% of participants reported improvement in quality of life.
Improvement was demonstrated in participants up to 34 years post-injury.
Support Our Community Partners
Read Our Publications
View Our Media Coverage
Explore Our Blog
All ONWARD® Medical devices and therapies referenced here, including but not limited to ARCIM®, ARCEX®, ARCBCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.
*Moritz, Chet, et al. “Non-invasive spinal cord stimulation for arm and hand function in chronic tetraplegia: a safety and efficacy trial.” Nature Medicine. 2024.